We advised ProKidney on the offering 

Davis Polk advised ProKidney Corp. in an SEC-registered underwritten public offering of 46,886,452 Class A ordinary shares and a concurrent SEC-registered direct offering of 11,030,574 Class A ordinary shares. ProKidney will receive an aggregate of approximately $140 million of gross proceeds from the offerings. ProKidney’s Class A ordinary shares are listed on Nasdaq under the symbol “PROK.”

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Steven Glendon, Joyce Kim and Hope Goimarac. The tax team included partner Patrick E. Sigmon, counsel Christopher A. Baratta and associate Michael Hsieh. The intellectual property team included partner David R. Bauer and associate Brette L. Trost. Partner Daniel P. Stipano provided financial institutions advice. Members of the Davis Polk team are based in the New York and Washington DC offices.